Je was op zoek naar: hydroxyurea (Engels - Sloveens)

prior hydroxyurea
predhodno zdravljenje s hidroksiureo

prior hydroxyurea prior interferon prior bone marrow transplant
predhodno zdravljenje s hidroksiureo predhodno zdravljenje z interferonom predhodna transplantacija kostnega mozga

it may be given with hydroxyurea or anagrelide if clinically indicated.
lahko se daje s hidroksiureo ali z anagrelidom, če je to klinično indicirano.

no inhibition of deferasirox metabolism by hydroxyurea was observed in vitro.
in vitro niso opazili nobene inhibicije metabolizma deferasiroksa zaradi hidroksiuree.

hence, hydroxyurea should not be used in the treatment of hiv infection.
hidroksisečnine zato ne smemo uporabljati pri zdravljenju okužb s hiv.

to compare the average time to response following treatment with anagrelide or hydroxyurea.
primerjava povprečnega časa, ki preteče do odgovora na zdravljenje z anagrelidom ali hidroksisečnino.

jakavi is also used to treat patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
zdravilo jakavi uporabljamo tudi za zdravljenje bolnikov s pravo policitemijo, pri katerih ne pride do ustreznega odziva na zdravljenje s hidroksiureo ali je ne prenašajo.

to compare the cytoreductive impact of anagrelide and hydroxyurea on white blood cell and red blood cell lines.
primerjava citoreduktivnega vpliva anagrelida in hidroksisečnine na linije levkocitov in eritrocitov.

jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
zdravilo jakavi je indicirano za zdravljenje odraslih bolnikov s pravo policitemijo, pri katerih ne pride do ustreznega odziva na zdravljenje s hidroksiureo ali je ne prenašajo.

most of these patients had histories of extended treatment with hydroxyurea and prior nmsc or pre-malignant skin lesions.
večina teh bolnikov je imela v anamnezi dolgotrajno zdravljenje s hidroksiureo in premaligne kožne spremembe oziroma predstopnje nemelanomskega kožnega raka.

in polycythaemia vera, jakavi was studied in one main study which involved 222 patients who were resistant or intolerant to treatment with hydroxyurea.
pri pravi policitemiji so zdravilo jakavi proučevali v eni glavni študiji, ki je vključevala 222 bolnikov, ki se niso odzivali na zdravljenje s hidroksisečnino ali je ne prenašajo.

in polycythaemia vera the chmp considered that jakavi is of benefit to patients who do not respond or are intolerant to treatment with hydroxyurea, while the safety profile is acceptable.
v zvezi s pravo policitemijo je menil, da zdravilo jakavi koristi bolnikom, ki se ne odzivajo na zdravljenje s hidroksisečnino ali je ne prenašajo.

to compare the safety of anagrelide and hydroxyurea in short and long term usage of up to three years with particular reference to cardiovascular safety (as assessed by echocardiography).
primarni primerjava varnosti anagrelida in hidroksisečnine pri kratkotrajnem in dolgotrajnem jemanju do treh let, s posebnim upoštevanjem kardiovaskularne varnosti (ocenjeno s pomočjo ehokardiografije).

hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in hiv infected patients treated with antiretroviral agents and hydroxyurea; fatal hepatic events were reported most often in patients treated with stavudine, hydroxyurea and didanosine.
v obdobju spremljanja zdravila po prihodu na trg so bili pri bolnikih, okuženih s hiv, ki so prejemali protiretrovirusna zdravila in hidroksisečnino, poročali o hepatotoksičnih učinkih in odpovedi jeter s smrtnim izidom; usodni jetrni dogodki so bili najpogosteje opisani pri bolnikih, ki so se zdravili s stavudinom, hidroksisečnino in didanozinom.

hydroxycarbamide, which used to be known as hydroxyurea, has been available in the european union (eu) for several decades for use in other illnesses, including some types of cancer.
hidroksikarbamid, nekdaj znan kot hidroksisečnina, je v evropski uniji (eu) že nekaj desetletij na voljo za uporabo pri drugih boleznih, vključno z nekaterimi vrstami raka.

bat was selected by the investigator on a patient-by- patient basis and included hydroxyurea (59.5%), interferon/pegylated interferon (11.7%), anagrelide (7.2%), pipobroman (1.8%) and observation (15.3%).
najboljše razpoložljivo zdravljenje je izbral raziskovalec za vsakega bolnika posamezno, in sicer pri 59,5 % bolnikov hidroksiureo, pri 11,7 % bolnikov interferon oziroma pegilirani interferon, pri 7,2 % bolnikov anagrelid, pri 1,8 % bolnikov pipobroman in pri 15,3 % bolnikov samo opazovanje.